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Abstract
Seven metallo-b-lactamase-positive isolates of Serratia marcescens were recovered from three patients hospitalized in a neonatal ward in
an Argentinean hospital during the period July–September 2011. All the isolates were multidrug-resistant, they belonged to a single
clone, and carried a blaVIM-16-containing class I integron structure. This represents the first nosocomial outbreak of metallo-b-lactamase
in Enterobacteriaceae in Argentina.
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The first transferable carbapenemase identified in Gram-nega-
tive bacteria was an IMP-like metallo-b-lactamase (MBL) in
the Far East, followed by VIM types in Europe [1,2]. Histori-
cally, MBLs were widespread in Pseudomonas aeruginosa and
Acinetobacter spp., but recently they have emerged in Entero-
bacteriaceae [3,4]. In South America, carbapenem resistance
in Enterobacteriaceae has been sporadically attributed to the
production of MBLs [5–7]. To our knowledge, there are no
previous reports of MBL-producing Serratia marcescens in
South America. In this study, we describe the first nosocomial
outbreak of S. marcescens producing blaVIM-16 in Argentina.
Seven isolates of carbapenem-resistant S. marcescens
belonging to three patients hospitalized in a neonatal ward of
a hospital in Buenos Aires city were recovered between July
and September 2011. Identification and routine susceptibility
tests of all the isolates were carried out using the Vitek sys-
tem (bioMe´rieux, Marcy L’E´toile, France). The MICs of imipe-
nem and ciprofloxacin were determined by E-test following
the manufacturer’s instructions (AB BIODISK, Solna, Sweden).
Results were interpreted according to the CLSI 2011
breakpoints [8]. For the phenotypic detection of carbapene-
mases, the modified Hodge test was performed and the
meropenem (10 lg) (Oxoid, Basingstoke, UK) -EDTA/sodium
mercaptoacetic acid (Laboratorios Britania, Buenos Aires,
Argentina) [8] and the meropenem (10 lg) -3-aminophenylbo-
ronic acid (300 lg) (Britania) synergy tests were applied.
Detection of blaVIM, blaIMP, blaNDM, blaKPC, blaCTX-M and
blaPER genes was performed in all the isolates by PCR ampli-
fication using specific primers and conditions that have been
described previously [9,10].The presence of class I integrons
was investigated using PCR amplification with primers for
the integrase gene IntI and specific primers for the conserved
segments 5¢CS and 3¢CS [11]. Genotyping of all the detected
isolates was performed by repetitive sequence-based PCR.
Patterns were considered different if they differed by more
than one band, regardless of the intensity [12].
The activities of colistin, rifampicin, ciprofloxacin, mino-
cycline, amikacin and their associations were evaluated by
means of killing curve assays to define possible therapies
against these multidrug-resistant isolates because of the lim-
ited therapeutic options available. The following concentra-
tions were used: colistin 4 mg/L; rifampicin 4 mg/L;
ciprofloxacin 2 mg/L; minocycline 2 mg/L and amikacin
4 mg/L. These concentrations were selected to reflect clini-
cally relevant levels, according to the serum levels reached
by the antimicrobial agents.
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To carry out rectal screening for the detection of carba-
penem-resistant enterobacteria, surveillance cultures were
routinely performed for all patients at admission and
repeated weekly. Samples were obtained using sterile swabs,
which were streaked onto plates containing CHROMagar
KPC medium (CHROMagar Company, Paris, France).
Clinical and epidemiological data of patients with carbape-
nem-resistant S. marcescens are shown in Table 1. All strains
showed resistance to ampicillin and amoxicillin/clavulanic acid
(MIC ‡ 32 mg/L), cefoxitin and cefotaxime (MIC ‡ 64 mg/L),
ceftazidime, imipenem and meropenem (MIC ‡ 16 mg/L),
gentamicin and amikacin (MIC ‡ 16 mg/L), minocycline
(MIC ‡8 mg/L) and rifampicin (MIC ‡ 64 mg/L) but remained
susceptible to aztreonam (MIC: 0.125 mg/L) and ciprofloxa-
cin (MIC £ 0.25 mg/L). The MICs to imipenem and ciproflox-
acin were also confirmed by E-test. The modified Hodge test
and the imipenem-EDTA/sodium mercaptoacetic acid were
positive for all carbapenem-resistant S. marcescens isolates,
whereas no synergy was observed with the imipenem-3-am-
inophenylboronic acid double-disk diffusion method. The
presence of blaVIM-16 was detected in the seven strains of
S. marcescens studied by PCR amplification followed by
sequencing. The PCR mapping indicated that blaVIM-16 was
part of a class I integron in all the isolates. Neither blaCTX-M
nor blaPER genes, which represent the most prevalent
extended spectrum b-lactamases in our country, were
detected [13]. The isolates showed indistinguishable band
patterns, which indicate clonal relatedness.
In Argentina, VIM-2 is the most frequent MBL found in
P. aeruginosa and other non-fermentative bacteria [11,14]. The
national surveillance programme previously detected two spo-
radic isolates of Providencia rettgeri and Enterobacter cloacae,
these strains carried blaVIM-2 and blaIMP-8, respectively [15].
VIM-16 is a new VIM-2 variant. It has only been reported
in P. aeruginosa urine isolates from Germany [16].
The index case was born in a medical centre of Gran Bue-
nos Aires and remained hospitalized by underlying diseases.
He was transferred to Sagrado Corazon medical centre for
diagnosis and treatment. Bacteriological screening of stools
obtained the day of his admission revealed the presence of
an MBL in the S. marcescens isolate; hence, we can affirm
that this patient had been previously colonized by this strain.
We were unable to determine the incidence of MBLs in the
original medical centre, and we lack information concerning
whether some relatives or hospital staff had travelled to
countries in which MBL-carbapenemase producers are wide-
spread. But, by the low incidence of VIM-16, it could be pos-
tulated that the MBL had been acquired domestically in the
first hospital, and had arisen under carbapenem pressure.
Despite the implementation of strict barriers precautions,
S. marcescens carrying blaVIM-16 was subsequently isolated
from samples belonging to two more patients during the fol-
lowing 2 weeks.
The isolates described in the present work remained sus-
ceptible to ciprofloxacin in spite of their multiresistance. This
profile, previously reported by other authors in carbapenem-
ase- producing Enterobacteriaceae [17], reflects the infre-
quent use of fluoroquinolones in neonatal and paediatrics
wards and the importance of antimicrobial pressure in the
selection of mechanisms of resistance. The use of combined
treatment is frequently suggested to improve the outcome
of these severe multidrug-resistant infections because of the
limited therapeutic options available and to prevent the
selection of resistance to the agent administered as mono-
therapy. Ciprofloxacin showed bacteriostatic activity,
whereas the associations of colistin with ciprofloxacin, mino-
cycline and rifampicin were indifferent in the killing curve
studies. These results are different to results obtained by
other authors in the late 1970s, which reported the pres-
ence of synergism between colistin and rifampicin [18]. How-
ever, those isolates were not multidrug-resistant like the
present isolates. Although amikacin in isolation did not pro-
duce inhibition, its combination with ciprofloxacin was syner-
gistic at 4 h. The patients underwent combination treatment
with ciprofloxacin-colistin (patient 1) and levofloxacin-
amikacin (patient 2); the therapy installed was successful in
the second patient. The third patient received therapy with
multiple antimicrobials, including colistin plus rifampicin for
concomitant infections; his surveillance cultures became
negative 4 weeks after the first isolation and he was dis-
charged from hospital when he was cured from his underly-
ing disease.
TABLE 1. Clinical and epidemiological data of patients
Patient Date of
admission
Date of
isolation Underlying diseases
Screening stool
specimen Site of isolationa
Infection (I) or
colonization (C) Treatment Evolution
1 24 July 24 July Congenital heart disease Yes RT-urine-blood- RS I Cip-col Death
2 18 July 4 Aug Meningitis Yes RTI-RS I Lev-ak Favourable
3 27 June 8 Aug Congenital heart disease Yes RS C – –
aExtra-intestinal.
Cip-col, ciprofloxacin + colistin; Lev-ak, levofloxacin + amikacin; RT, respiratory tract; RS, rectal swab.
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In conclusion, we report the first nosocomial outbreak of
MBL-positive isolates in Enterobacteriaceae in Argentina. We
believe that surveillance policies and rapid detection methods
should be implemented in each medical centre to avoid the
dissemination of these multidrug-resistant isolates and pre-
vent future outbreaks.
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